Provided by Tiger Trade Technology Pte. Ltd.

Global X Aging Population ETF

37.04
+0.45161.23%
Volume:6K
Turnover:216.99K
Market Cap:91.48M
PE:- -
High:37.24
Open:37.02
Low:37.02
Close:36.59
52wk High:39.48
52wk Low:32.44
Shares:2.47M
Float Shares:2.47M
Volume Ratio:1.10
T/O Rate:0.24%
Dividend:0.33
Dividend Rate:0.89%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Welltower Director Andrew Gundlach Reports $2.42 Million Common Share Purchase

Reuters
·
Aug 28

Eli Lilly (LLY) Says Zepbound Cuts Healthcare Costs For Adults Over 55

Simply Wall St.
·
Aug 27

China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs

Reuters
·
Aug 27

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

Reuters
·
Aug 27

Recombinant Collagen Leader Faces Growth Challenges After Weak Interim Results

Deep News
·
Aug 27

AbbVie Seeks EMA Approval for Skyrizi Subcutaneous Induction in Crohn’s Disease

Reuters
·
Aug 27

Abbvie Submits Regulatory Application to Ema for Skyrizi® (Risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

THOMSON REUTERS
·
Aug 27

Biotron Posts Wider Annual Loss but Boosts Asset Backing Amid Material Uncertainty

TIPRANKS
·
Aug 27

Edwards Lifesciences CVP JAPAC Wayne Markowitz Sells 1,240 Shares for $113,416.60

Reuters
·
Aug 27

Eli Lilly & Co. Stock Slips 3.6%, Underperforms Peers

Dow Jones
·
Aug 27

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Aug 27

Sector Update: Healthcare

MT Newswires Live
·
Aug 27

Eli Lilly Expands Alzheimer’s Pipeline With New Amyloid Phase 1 Trial

TIPRANKS
·
Aug 27

Eli Lilly Stock (LLY) in Focus as Alzheimer’s Blood Test Gets FDA Approval

TIPRANKS
·
Aug 26

Boston Scientific Hit by Cyberattack, Shares Slide on Delivery Disruption

Deep News
·
Aug 26

Eli Lilly and Co Stock (LLY) Opened Down by 3.57% on Aug 26: Facts Behind the Movement

TradingKey
·
Aug 26

Eli Lilly Study Shows Lower Healthcare Costs With Zepbound in Older Adults

MT Newswires Live
·
Aug 26

Gubra Earns USD 50 Million Milestone as AbbVie Starts Phase 2 Trial of Obesity Drug ABBV-295

Reuters
·
Aug 26

Zepbound Linked to Lower Healthcare Costs in Adults over Age 55 with Obesity According to a Real-World Study

THOMSON REUTERS
·
Aug 26

Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes

Reuters
·
Aug 26